anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab

Alessandro Armuzzi, P. Lionetti, C. Blandizzi, R. Caporali, S. Chimenti, L. Cimino, P. Gionchetti, G. Girolomoni, G. Lapadula, A. Marchesoni, A. Marcellusi, F. S. Mennini, C. Salvarani, R. Cimaz

Risultato della ricerca: Contributo in rivistaArticolo in rivista

39 Citazioni (Scopus)

Abstract

The complex pathogenesis of immune-mediated inflammatory diseases (IMIDs) has been extensively investigated and dysregulation of cytokines, such as tumour necrosis factor (TNF) has been shown to play a dominant role in the pathogenesis of various IMIDs, such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis and psoriatic arthritis. The subsequent development of biological agents capable of blocking TNF has led to important advances in the pharmacotherapy of such diseases and confirmed the concept of a common pathophysiology among IMIDs with TNF having a predominant role. Five TNF inhibitors have currently been approved for treatment of one or more IMIDs; these include infliximab, etanercept, adalimumab, golimumab and certolizumab pegol. Given the similarities in the pathogenic background of IMIDs, one could expect that anti-TNF agents be similarly effective and with comparable tolerability profiles; however, this may not be the case. Structural and pharmacological differences among the anti-TNF drugs are likely to result in differences in efficacy and tolerability among the agents in the different IMIDs, together with differences in potency, therapeutic dose ranges, dosing regimens, administration routes, and propensity for immunogenicity. Among the five TNF inhibitors approved for treatment of IMIDs, adalimumab has the widest range of indications. Data from controlled clinical trials of adalimumab, showing its excellent efficacy and tolerability in a wide range of indications, are supported by real-world long-term data from observational studies, which confirm the value of adalimumab as a suitable choice in the management of IMIDs.
Lingua originaleEnglish
pagine (da-a)11-32
Numero di pagine22
RivistaInternational Journal of Immunopathology and Pharmacology
Volume27
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • Animals
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal, Humanized
  • Autoimmune Diseases
  • Clinical Trials as Topic
  • Humans
  • Inflammation
  • Structure-Activity Relationship
  • Tumor Necrosis Factor-alpha

Fingerprint Entra nei temi di ricerca di 'anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab'. Insieme formano una fingerprint unica.

Cita questo